UBS AM
ALT icon

UBS AM’s Altimmune ALT Stock Holding History

UBS AM’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6K Hold
4,154
– – ﹤0.01% 3222
2026
Q1 		$12.8K Buy
4,154
+3,482
+518% +$14.8K ﹤0.01% 3247
2025
Q4 		$2.43K Buy
+672
New +$2.93K ﹤0.01% 3104
2025
Q3 		– Sell
-4,215
Closed -$16.3K – 2284
2025
Q2 		$16.3K Sell
4,215
-102,657
-96% -$556K ﹤0.01% 2612
2025
Q1 		$534K Buy
106,872
+14,480
+16% +$91.7K ﹤0.01% 2487
2024
Q4 		$666K Buy
92,392
+13,126
+17% +$100K ﹤0.01% 2502
2024
Q3 		$487K Sell
79,266
-25,916
-25% -$176K ﹤0.01% 2651
2024
Q2 		$699K Buy
105,182
+86,982
+478% +$642K ﹤0.01% 2531
2024
Q1 		$185K Buy
+18,200
New +$185K ﹤0.01% 2471
2023
Q3 		– Sell
-19,200
Closed -$81K – 2590
2023
Q2 		$81K Hold
19,200
– – ﹤0.01% 2651
2023
Q1 		$81K Sell
19,200
-35,500
-65% -$422K ﹤0.01% 2651
2022
Q4 		$900K Buy
+54,700
New +$614K ﹤0.01% 1900

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's ALT Position: Q2 2026 in Review

UBS AM held its Altimmune (ALT) position steady in Q2 2026 at 4,154 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3222.

UBS AM first reported a position in ALT in Q4 2022 and has held it in 12 quarters since. The position peaked at $900K in Q4 2022. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • UBS AM held 4,154 shares of Altimmune worth $12.6K as of Q2 2026.
  • UBS AM left its Altimmune share count unchanged in Q2 2026.
  • Altimmune made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3222 holding.
  • UBS AM first reported a position in Altimmune in Q4 2022 and has held it in 12 quarters since.
  • UBS AM's Altimmune position peaked at $900K in Q4 2022.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.